Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden
globally and an increasing challenge in Asian countries. Treatment options include …

Objectives To estimate the incremental cost per life-year gained (LYG) of aflibercept in
combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) …

Background Safety and effectiveness of aflibercept with 5‐fluorouracil/levofolinate/irinotecan
have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a …

Aflibercept, a recombinant fusion protein, is a potent inhibitor of vascular endothelial growth
factor (VEGF)-A, VEGF-B, and the placental growth factor (PlGF). The present study was an …

Background The objectives of this study were to evaluate the safety profile of aflibercept and
health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) …

Background The Ph 3 VELOUR study demonstrated that addition of aflibercept (ziv-
aflibercept [USA]) to fixed-dose FOLFIRI improved survival outcomes & response rates in …

Objective: Aflibercept increased overall survival with acceptable tolerability in metastatic
colorectal cancer (mCRC) when it was used in combination with FOLFIRI after progression …

What is known and Objective Aflibercept, a recombinant protein designed to suppress the
vascular endothelial growth factor (VEGF) signalling pathway, has been used in patients …

Introduction Anti-angiogenic drugs are an efficacious class of therapy in the treatment of
patients with metastatic colorectal cancer (mCRC). Aflibercept, a vascular endothelial growth …